BioRestorative Therapies Inc (NASDAQ:BRTX) has a beta value of 61.79 and has seen 14.73 million shares traded in the recent trading session. The company, currently valued at $9.14M, closed the recent trade at $1.35 per share which meant it gained $0.11 on the day or 8.90% during that session. The BRTX stock price is -428.15% off its 52-week high price of $7.13 and 11.11% above the 52-week low of $1.20. The 3-month trading volume is 668.85K shares.
BioRestorative Therapies Inc (NASDAQ:BRTX) trade information
Sporting 8.90% in the green today, the stock has traded in the green over the last five days, when the BRTX stock price touched $1.35 or saw a rise of 12.34%. Year-to-date, BioRestorative Therapies Inc shares have moved -22.39%, while the 5-day performance has seen it change 0.78%. Over the past 30 days, the shares of BioRestorative Therapies Inc (NASDAQ:BRTX) have changed -3.54%.
BioRestorative Therapies Inc (BRTX) estimates and forecasts
Figures show that BioRestorative Therapies Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -28.17% over the past 6 months, with this year growth rate of 42.69%, compared to 12.60% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 66.70% and 40.30% for the next quarter. Revenue growth from the last financial year stood is estimated to be -17.80%.
1 analysts offering their estimates for the company have set an average revenue estimate of $30k for the current quarter. 1 have an estimated revenue figure of $30k for the next quarter concluding in Jun 2024. Year-ago sales stood $31k and $65k respectively for this quarter and the next, and analysts expect sales will shrink by -3.20% for the current quarter and -53.80% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 77.95% over the past 5 years.
BRTX Dividends
BioRestorative Therapies Inc is expected to release its next earnings report in May this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
